Literature DB >> 30141893

Effective pH-Activated Theranostic Platform for Synchronous Magnetic Resonance Imaging Diagnosis and Chemotherapy.

Dan Wang1, Haiyan Lin2, Guilong Zhang, Yuanchun Si1, Hongyi Yang, Guo Bai3, Chi Yang3, Kai Zhong, Dongqing Cai, Zhengyan Wu, Renfei Wang2, Duohong Zou1,3.   

Abstract

Current magnetic resonance imaging (MRI)-guided pH-switching therapeutic platforms have encountered problems such as low relaxation rates, poor pH-switching efficiencies, and a lag in the drug release behind the MRI. Herein, we designed a nanoplatform with tunable pore size, which could match the size of drug molecules for pH-switching MRI and chemotherapy via ultrasmall manganese oxide-capped mesoporous silica nanoparticles (USMO@MSNs). USMO@MSN could quickly dissolve under weakly acidic conditions and leach abundant Mn2+ ions (leaching ratio: 76%), enhancing the MR contrast. The longitudinal relaxation rate ( r1) of USMO@MSNs significantly increased from 0.65 to 5.61 mM-1 s-1 as the pH decreased from 7.4 to 4.5, showing an ultrahigh-efficiency pH-switching T1-weighted MR contrast ability for in vivo tumor. Meanwhile, the matching pore structure allowed effective loading of doxorubicin (DOX) on USMO@MSNs to form smart therapeutic system (USMO@MSNs-DOX). The DOX release rate was strongly proportional to the pH-switching MRI signal of USMO@MSNs-DOX, allowing the release of DOX to be efficiently monitored by MRI. Confocal observations indicated that USMO@MSNs-DOX could be effectively internalized by HSC3 cells, and the entire system showed a good pH-switching theranostic performance for HSC3 cells. Therefore, this simple pH-switching system provides a new avenue for timely cancer diagnosis and personalized therapy.

Entities:  

Keywords:  MRI; pH-activated; synchronous; theranostic platform; tumor chemotherapy

Mesh:

Substances:

Year:  2018        PMID: 30141893     DOI: 10.1021/acsami.8b11408

Source DB:  PubMed          Journal:  ACS Appl Mater Interfaces        ISSN: 1944-8244            Impact factor:   9.229


  8 in total

Review 1.  Manganese Oxide Nanoparticles As MRI Contrast Agents In Tumor Multimodal Imaging And Therapy.

Authors:  Xiaoxia Cai; Qingxia Zhu; Yun Zeng; Qi Zeng; Xueli Chen; Yonghua Zhan
Journal:  Int J Nanomedicine       Date:  2019-10-21

Review 2.  Chemotherapeutic nanomaterials in tumor boundary delineation: Prospects for effective tumor treatment.

Authors:  Ozioma Udochukwu Akakuru; Zhoujing Zhang; M Zubair Iqbal; Chengjie Zhu; Yewei Zhang; Aiguo Wu
Journal:  Acta Pharm Sin B       Date:  2022-02-23       Impact factor: 14.903

Review 3.  Mesoporous Silica Nanoparticles as Theranostic Antitumoral Nanomedicines.

Authors:  Alejandro Baeza; Maria Vallet-Regí
Journal:  Pharmaceutics       Date:  2020-10-11       Impact factor: 6.321

Review 4.  Nanoarchitectured prototypes of mesoporous silica nanoparticles for innovative biomedical applications.

Authors:  Ranjith Kumar Kankala; Ya-Hui Han; Hong-Ying Xia; Shi-Bin Wang; Ai-Zheng Chen
Journal:  J Nanobiotechnology       Date:  2022-03-12       Impact factor: 10.435

Review 5.  The Renal Clearable Magnetic Resonance Imaging Contrast Agents: State of the Art and Recent Advances.

Authors:  Xiaodong Li; Yanhong Sun; Lina Ma; Guifeng Liu; Zhenxin Wang
Journal:  Molecules       Date:  2020-11-01       Impact factor: 4.411

6.  L-EGCG-Mn nanoparticles as a pH-sensitive MRI contrast agent.

Authors:  Jiali Li; Xue Jiang; Lihuan Shang; Zhen Li; Conglian Yang; Yan Luo; Daoyu Hu; Yaqi Shen; Zhiping Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.419

Review 7.  Targeted Drug Delivery and Theranostic Strategies in Malignant Lymphomas.

Authors:  Tomas Etrych; Alena Braunova; David Zogala; Lukas Lambert; Nicol Renesova; Pavel Klener
Journal:  Cancers (Basel)       Date:  2022-01-26       Impact factor: 6.639

8.  Dual Modal Imaging-Guided Drug Delivery System for Combined Chemo-Photothermal Melanoma Therapy.

Authors:  Dong Zhang; Weifen Zhang; Xinghan Wu; Qian Li; Zhiyi Mu; Fengshuo Sun; Mogen Zhang; Guoyan Liu; Linlin Hu
Journal:  Int J Nanomedicine       Date:  2021-05-18
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.